title: Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic clamp estimates in rats.
abstract: Assessing insulin resistance in rodent models gives insight into mechanisms that cause type 2 diabetes and the metabolic syndrome. The hyperinsulinemic euglycemic glucose clamp, the reference standard for measuring insulin sensitivity in humans and animals, is labor intensive and technically demanding. A number of simple surrogate indexes of insulin sensitivity/resistance have been developed and validated primarily for use in large human studies. These same surrogates are also frequently used in rodent studies. However, in general, these indexes have not been rigorously evaluated in animals. In a recent validation study in mice, we demonstrated that surrogates have a weaker correlation with glucose clamp estimates of insulin sensitivity/resistance than in humans. This may be due to increased technical difficulties in mice and/or intrinsic differences between human and rodent physiology. To help distinguish among these possibilities, in the present study, using data from rats substantially larger than mice, we compared the clamp glucose infusion rate (GIR) with surrogate indexes, including QUICKI, HOMA, 1/HOMA, log (HOMA), and 1/fasting insulin. All surrogates were modestly correlated with GIR (r = 0.34-0.40). Calibration analyses of surrogates adjusted for body weight demonstrated similar predictive accuracy for GIR among all surrogates. We conclude that linear correlations of surrogate indexes with clamp estimates and predictive accuracy of surrogate indexes in rats are similar to those in mice (but not as substantial as in humans). This additional rat study (taken with the previous mouse study) suggests that application of surrogate insulin sensitivity indexes developed for humans may not be appropriate for determining primary outcomes in rodent studies due to intrinsic differences in metabolic physiology. However, use of surrogates may be appropriate in rodents, where feasibility of clamps is an obstacle and measurement of insulin sensitivity is a secondary outcome.
authors.affiliation: Diabetes Unit, NCCAM, NIH, 9 Memorial Dr., Bldg. 9, Rm. 1N-105 MSC 0920, Bethesda, MD 20892-0920, USA. quonm@nih.gov
authors.forename: Ranganath
authors.initials: R
authors.lastname: Muniyappa
authors.forename: Hui
authors.initials: H
authors.lastname: Chen
authors.forename: Radhika H
authors.initials: RH
authors.lastname: Muzumdar
authors.forename: Francine H
authors.initials: FH
authors.lastname: Einstein
authors.forename: Xu
authors.initials: X
authors.lastname: Yan
authors.forename: Lilly Q
authors.initials: LQ
authors.lastname: Yue
authors.forename: Nir
authors.initials: N
authors.lastname: Barzilai
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Quon
mesh_terms: D000818:Animals; D001835:Body Weight / Q000502:physiology; D002138:Calibration; D005215:Fasting / Q000378:metabolism; D005260:Female; D015309:Glucose Clamp Technique; D006706:Homeostasis / Q000502:physiology; D006946:Hyperinsulinism / Q000378:metabolism*; D007333:Insulin Resistance / Q000502:physiology*; D016014:Linear Models; D011237:Predictive Value of Tests; D051381:Rats; D017207:Rats, Sprague-Dawley
references.citation: Diabetes. 2002 Oct;51(10):2951-8
references.pmid: 12351432
references.citation: Diabetes Care. 2003 Aug;26(8):2426-32
references.pmid: 12882874
references.citation: Endocr Rev. 2007 Feb;28(1):48-83
references.pmid: 17018838
references.citation: Circ Res. 2007 May 25;100(10):1415-27
references.pmid: 17525381
references.citation: J Clin Endocrinol Metab. 2004 Mar;89(3):1481-4
references.pmid: 15001651
references.citation: J Clin Endocrinol Metab. 2004 Jan;89(1):135-41
references.pmid: 14715840
references.citation: Physiol Rev. 2004 Apr;84(2):623-47
references.pmid: 15044684
references.citation: Diabetes Care. 1999 Sep;22(9):1462-70
references.pmid: 10480510
references.citation: Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E451-5
references.pmid: 18073320
references.citation: Med Clin North Am. 2004 Jul;88(4):787-835, ix
references.pmid: 15308380
references.citation: Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
references.pmid: 17957034
references.citation: Diabetes. 2007 May;56(5):1268-76
references.pmid: 17303807
references.citation: Nat Med. 2002 Jul;8(7):731-7
references.pmid: 12068289
references.citation: Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E985-91
references.pmid: 10826999
references.citation: Contemp Top Lab Anim Sci. 2004 Nov;43(6):42-51
references.pmid: 15669134
references.citation: Am J Physiol Endocrinol Metab. 2007 May;292(5):E1378-87
references.pmid: 17227956
references.citation: Diabetes. 2006 Oct;55(10):2788-96
references.pmid: 17003344
references.citation: J Clin Endocrinol Metab. 2001 Nov;86(11):5457-64
references.pmid: 11701722
references.citation: PLoS One. 2009 Jul 22;4(7):e6334
references.pmid: 19623253
references.citation: Am J Physiol Regul Integr Comp Physiol. 2000 Jan;278(1):R111-7
references.pmid: 10644628
references.citation: Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6086-91
references.pmid: 15837923
references.citation: Diabetes. 2006 Dec;55(12):3594-603
references.pmid: 17130509
references.citation: Am J Physiol Endocrinol Metab. 2008 Feb;294(2):E261-70
references.pmid: 18003716
references.citation: Best Pract Res Clin Endocrinol Metab. 2003 Sep;17(3):305-22
references.pmid: 12962688
references.citation: Diabetes. 2005 Jul;54(7):1914-25
references.pmid: 15983190
references.citation: J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
references.pmid: 10902785
references.citation: Diabetologia. 1985 Jul;28(7):412-9
references.pmid: 3899825
references.citation: Am J Physiol Endocrinol Metab. 2008 Nov;295(5):E1269-76
references.pmid: 18796548
references.citation: Recent Prog Horm Res. 2004;59:207-23
references.pmid: 14749503
references.citation: Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E804-12
references.pmid: 12678026